Oral anticoagulation is a milestone in the management of atrial fibrillation (AF). In complex settings, involving some kinds of thrombophilia, a condition predisposing to higher risk of thromboembolism, warfarin can be ineffective. Direct oral anticoagulants (DOACs) demonstrated to be a valid therapeutic option; in particular edoxaban proved to be effective and safe. We show the case of a man with AF and thrombophilia who developed a thrombus in the left atrial appendage (LAA) despite anticoagulant therapy with warfarin, subsequently treated with edoxaban.
Atrial fibrillation and thrombophilia. DOAC as a valid alternative? A clinical case
Claudia MorabitoPrimo
Investigation
;Pasquale CreaInvestigation
;Luca ZappiaInvestigation
;Roberto LicordariInvestigation
;Alessandro MiglioratoInvestigation
;Francesco LuzzaPenultimo
Investigation
;Giuseppe DattiloUltimo
Supervision
2020-01-01
Abstract
Oral anticoagulation is a milestone in the management of atrial fibrillation (AF). In complex settings, involving some kinds of thrombophilia, a condition predisposing to higher risk of thromboembolism, warfarin can be ineffective. Direct oral anticoagulants (DOACs) demonstrated to be a valid therapeutic option; in particular edoxaban proved to be effective and safe. We show the case of a man with AF and thrombophilia who developed a thrombus in the left atrial appendage (LAA) despite anticoagulant therapy with warfarin, subsequently treated with edoxaban.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.